hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic ...

"This increased our interest in the epidermal growth factor receptor (EGFR) pathway because previous work indicated that it ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for ...

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today ...

Dizal seeks US FDA approval for sunvozertinib to treat relapsed or refractory NSCLC with EGFR Exon 20 insertion mutations: Shanghai, China Saturday, November 9, 2024, 17:00 Hrs [I ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, ...